Hepatitis C Positive Organ to Recipient Hepatitis C Negative Longitudinal Transplant Study

Yale University49 enrolled

Overview

Compare wait list mortality and time to liver, heart or kidney transplant for registrants listed to consider allografts from Hepatitis C Virus (HCV) Nucleic Amplification Testing (NAT)+ donors versus those who are not . The umbrella protocol has been set up to include heart and kidney transplant recipients.

The research project will take place within each transplant center and can be incorporated into routine pre- and post-transplant care (i.e., no extra visits are needed). Enrolling in this study will enable patients to accept offers of HCV NAT+ livers, in addition to the regular waitlist. All other transplant eligibility criteria have to be met per routine care. The multi-site project will establish a biorepository and prospective data collection with the goal of obtaining more generalizable results than single-center studies alone can. Patients who enroll in the study but receive an HCV- organ instead, will be (data collection only) as part of the study. Aims are to evaluate sustained virologic response (SVR) rates post-transplant with Direct Acting Anti-Viral (DAA) therapy, as well as long-term patient and graft outcomes. Evaluate the financial impact of timely transplant and DAA therapy compared to traditional wait time health care expenditure. Create a blood and tissue biorepository for future evaluation of HCV NAT+ allografts and their outcomes

Study Type

OBSERVATIONAL

Enrollment

Conditions

Liver Transplant; Complications Hepatitis C

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Recipient Inclusion Criteria: 1. Adult patients \> or = 18 years of age 2. Actively listed for Liver Transplant (LT) or Simultaneous Liver and Kidney (SLK) 3. Current HCV NAT- status 4. Review by multi-disciplinary transplant team that patient is appropriate for listing for HCV NAT+ liver offers Recipient Exclusion Criteria: 1. Unwilling to consent to post transplant DAA therapy 2. Hepatitis B Virus (HBV) viremia Donor Inclusion Criteria: 1. HCV NAT+ 2. Deceased Donor organs 3. HBV cAb donors will be considered on a case by case basis based on specific recipient factors and plan for post-transplant prophylaxis Donor Exclusion Criteria: 1. Bilirubin \>3 2. Positive nucleotide testing for HBV 3. Radiographic, laboratory or other clinical evidence of portal hypertension 4. Fibrosis on pre-procurement liver biopsy fibrosis \> F1 or fibroscan \>7 (if both are done and discordant, use biopsy to determine eligibility

Locations (1)

Yale School of Medicine

New Haven, Connecticut, United States

Outcomes

Primary Outcomes

Time to Transplant

Number of days between date of adding patient to the waitlist and transplant date comparing waitlist registrants listed to accept HCV NAT+ donor organs with those followed per standard of care (not accepting HCV NAT+ donor organs).

Time frame: 5 years

Secondary Outcomes

Wait list Mortality

Number of days between adding patient to the waitlist to death on the waitlist comparing waitlist registrants listed to accept HCV NAT+ donor organs with those followed per standard of care (not accepting HCV NAT+ donor organs).

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.